What was the market valuation of the US car t-cell-therapy market in 2024?

The market valuation was $1939.98 Million in 2024. Read More

What is the projected market valuation for the US car t-cell-therapy market by 2035?

The projected valuation for 2035 is $9449.16 Million. Read More

What is the expected CAGR for the US car t-cell-therapy market during the forecast period 2025 - 2035?

The expected CAGR during this period is 15.48%. Read More

Which therapeutic areas are leading in the US car t-cell-therapy market?

Oncology leads with a valuation range from $1160.0 Million to $5500.0 Million. Read More

What are the key cell sources utilized in the US car t-cell-therapy market?

The key cell sources include Autologous, Allogeneic, and Gene-Edited, with Autologous valued between $1160.0 Million and $5500.0 Million. Read More

Which indications are most prevalent in the US car t-cell-therapy market?

Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma are significant, with valuations of $500.0 Million and $800.0 Million, respectively. Read More

What are the primary end users of car t-cell-therapy in the US market?

Hospitals are the primary end users, with a valuation range from $800.0 Million to $3800.0 Million. Read More

Who are the key players in the US car t-cell-therapy market?

Key players include Gilead Sciences, Novartis, Bristol-Myers Squibb, and others. Read More

What is the market potential for autoimmune diseases in the US car t-cell-therapy market?

The market potential for autoimmune diseases ranges from $500.0 Million to $2500.0 Million. Read More

How does the US car t-cell-therapy market compare to other therapeutic areas?

Oncology dominates, while other areas like Autoimmune Diseases and Infectious Diseases show potential with valuations of $500.0 Million to $2500.0 Million. Read More

What will be the market value of the US Car T Cell Therapy Market by 2035?

By 2035, the market is projected to reach a value of 11.0 billion USD. Read More

What is the expected CAGR for the US Car T Cell Therapy Market from 2025 to 2035?

The market is anticipated to grow at a CAGR of 16.763% during the forecast period from 2025 to 2035. Read More

What is the projected market size for the Oncology segment of the US Car T Cell Therapy Market in 2035?

The Oncology segment is expected to reach 6.0 billion USD in market size by 2035. Read More

Which companies are key players in the US Car T Cell Therapy Market?

Major players in the market include Legend Biotech, Bristol Myers Squibb, Novartis, and Gilead Sciences, among others. Read More

What is the expected market valuation for Autoimmune Diseases in the US Car T Cell Therapy Market in 2035?

The market for Autoimmune Diseases is expected to be valued at 3.0 billion USD by 2035. Read More

How much is the US Car T Cell Therapy Market for Infectious Diseases projected to be in 2024?

In 2024, the market for Infectious Diseases is projected to be valued at 0.4 billion USD. Read More

What are the growth opportunities within the US Car T Cell Therapy Market?

There are significant growth opportunities in oncology, autoimmune disorders, and the expanding use of personalized therapies. Read More

What are the main applications of Car T Cell Therapy in the US market?

The primary applications include treatment for oncology, autoimmune diseases, and infectious diseases. Read More

How does the growth rate of the US Car T Cell Therapy Market compare across different therapeutic areas?

The growth rate is particularly strong in oncology, where the market is projected to expand significantly by 2035. Read More

US CAR T Cell Therapy Market

ID: MRFR/Pharma/11329-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Car T Cell Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma) and By End Users (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth Outlook & Industry Forecast 2025 To 2035

US CAR T Cell Therapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Therapeutic Area (USD Million)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Diseases
  3. 4.1.3 Infectious Diseases
2. 4.2 Food, Beverages & Nutrition, BY Cell Source (USD Million)
  1. 4.2.1 Autologous
  2. 4.2.2 Allogeneic
  3. 4.2.3 Gene-Edited
3. 4.3 Food, Beverages & Nutrition, BY Indication (USD Million)
  1. 4.3.1 Acute Lymphoblastic Leukemia
  2. 4.3.2 Non-Hodgkin Lymphoma
  3. 4.3.3 Multiple Myeloma
4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Research Institutes
  3. 4.4.3 Cancer Treatment Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Celgene (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bluebird Bio (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Celyad Oncology (BE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY THERAPEUTIC AREA
3. 6.3 US MARKET ANALYSIS BY CELL SOURCE
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY CELL SOURCE, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY CELL SOURCE, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL SOURCE, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Therapeutic Area (USD Million, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases

Food, Beverages & Nutrition By Cell Source (USD Million, 2025-2035)

Autologous
Allogeneic
Gene-Edited

Food, Beverages & Nutrition By Indication (USD Million, 2025-2035)

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma

Food, Beverages & Nutrition By End User (USD Million, 2025-2035)

Hospitals
Research Institutes
Cancer Treatment Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”